Evidence map›Paper›PMID 26341519›Full record

ArticleRespiratory research2015

Impaired cardiac and peripheral hemodynamic responses to inhaled β₂-agonist in cystic fibrosis.

Erik H Van Iterson, Stephen R Karpen, Sarah E Baker, Courtney M Wheatley, Wayne J Morgan, Eric M Snyder

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Exercise Stroke Volume in Adult Cystic Fibrosis: A Comparison of Acetylene Pulmonary Uptake and Oxygen Pulse.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2018
    Article
  4. Subclinical Left Ventricular Dysfunction is Influenced by Genotype Severity in Patients with Cystic Fibrosis.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2018
    Article
  5. Article
  6. Review
  7. Evidence of microvascular dysfunction in patients with cystic fibrosis.American journal of physiology. Heart and circulatory physiology · 2016
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Erik H Van ItersonSchool of Kinesiology, University of Minnesota, Cooke Hall, 1900 University Ave SE., Minneapolis, MN, 55455, USA. vanit001@umn.edu.
Stephen R KarpenCollege of Pharmacy, University of Arizona, 1295 N Martin Ave, Tucson, AZ, 85721, USA. karpen@pharmacy.arizona.edu.
Sarah E BakerCollege of Pharmacy, University of Arizona, 1295 N Martin Ave, Tucson, AZ, 85721, USA. baker.sarah@mayo.edu.
Courtney M WheatleyCollege of Pharmacy, University of Arizona, 1295 N Martin Ave, Tucson, AZ, 85721, USA. wheatley.courtney@mayo.edu.
Wayne J MorganDepartment of Pediatrics, University of Arizona, 1501 N. Campbell Avenue, Room 3301, Tucson, AZ, 85724, USA. wmorgan@arc.arizona.edu.
Eric M SnyderSchool of Kinesiology, University of Minnesota, Cooke Hall, 1900 University Ave SE., Minneapolis, MN, 55455, USA. snyd0180@umn.edu.
University of Arizona · USUniversity of Minnesota · US

Funding

Gene-by-Gene Interactions and Lung Fluid Balance in Patients with Heart FailureR01HL108962 · NHLBI · UNIVERSITY OF MINNESOTA · PI SNYDER, ERIC M · 2011 to 2016
$2.2M
NHLBI NIH HHS HL108962-03NHLBI NIH HHS R01 HL108962
6 · The paper itself

Abstract

backgroundPulmonary system dysfunction is a hallmark of cystic fibrosis (CF) disease. In addition to impaired cystic fibrosis transmembrane conductance regulator protein, dysfunctional β2-adrenergic receptors (β2AR) contribute to low airway function in CF. Recent observations suggest CF may also be associated with impaired cardiac function that is demonstrated by attenuated cardiac output (Q), stroke volume (SV), and cardiac power (CP) at both rest and during exercise. However, β2AR regulation of cardiac and peripheral vascular tissue, in-vivo, is unknown in CF. We have previously demonstrated that the administration of an inhaled β-agonist increases SV and Q while also decreasing SVR in healthy individuals. Therefore, we aimed to assess cardiac and peripheral hemodynamic responses to the selective β2AR agonist albuterol in individuals with CF.

methods18 CF and 30 control (CTL) subjects participated (ages 22 ± 2 versus 27 ± 2 and BSA = 1.7 ± 0.1 versus 1.8 ± 0.0 m(2), both p < 0.05). We assessed the following at baseline and at 30- and 60-minutes following nebulized albuterol (2.5mg diluted in 3.0mL of normal saline) inhalation: 12-lead ECG for HR, manual sphygmomanometry for systolic and diastolic blood pressure (SBP and DBP, respectively), acetylene rebreathe for Q and SV. We calculated MAP = DBP + 1/3(SBP-DBP); systemic vascular resistance (SVR) = (MAP/Q)•80; CP = Q•MAP; stroke work (SW) = SV•MAP; reserve (%change baseline to 30- or 60-minutes). Hemodynamics were indexed to BSA (QI, SVI, SWI, CPI, SVRI).

resultsAt baseline, CF demonstrated lower SV, SVI, SW, and SWI but higher HR than CTL (p < 0.05); other measures did not differ. At 30-minutes, CF demonstrated higher HR and SVRI, but lower Q, SV, SVI, CP, CPI, SW, and SWI versus CTL (p < 0.05). At 60-minutes, CF demonstrated higher HR, SVR, and SVRI, whereas all cardiac hemodynamics were lower than CTL (p < 0.05). Reserves of CP, SW, and SVR were lower in CF versus CTL at both 30 and 60-minutes (p < 0.05).

conclusionsCardiac and peripheral hemodynamic responsiveness to acute β2AR stimulation via albuterol is attenuated in individuals with CF, suggesting β2AR located in cardiac and peripheral vascular tissue may be dysfunctional in this population.

Indexed as

Administration, InhalationAdrenergic beta-2 Receptor AgonistsAdultAlbuterolCardiac OutputCardiovascular SystemCase-Control StudiesCross-Sectional StudiesCystic FibrosisFemaleHemodynamicsHumansLungMaleNebulizers and VaporizersReceptors, Adrenergic, beta-2ADRB2 protein, humanAdrenergic beta-2 Receptor AgonistsAlbuterolReceptors, Adrenergic, beta-2

Identifiers

PMID26341519
PMCPMC4560914
OpenAlexW2102095033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.